Literature DB >> 22383679

EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.

L Fornaro1, F Crea2, G Masi3, E Paolicchi2, F Loupakis3, F Graziano4, L Salvatore3, M Ronzoni5, V Ricci5, C Cremolini3, M Schirripa3, R Danesi2, A Falcone3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22383679     DOI: 10.1093/annonc/mds031

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

Review 1.  Examining the impact of gene variants on histone lysine methylation.

Authors:  Capucine Van Rechem; Johnathan R Whetstine
Journal:  Biochim Biophys Acta       Date:  2014-05-23

2.  Association between EZH2 polymorphisms and colorectal cancer risk in Han Chinese population.

Authors:  Jian Wang; Zhen-Bin Ma; Kun Li; Guang-Hong Guo
Journal:  Med Oncol       Date:  2014-02-02       Impact factor: 3.064

3.  Role of EZH2 polymorphisms in esophageal squamous cell carcinoma risk in Han Chinese population.

Authors:  Zhen-Bin Ma; Guang-Hong Guo; Qiong Niu; Ning Shi
Journal:  Int J Mol Sci       Date:  2014-07-17       Impact factor: 5.923

4.  Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.

Authors:  Lorenzo Fornaro; Pinuccia Faviana; Veronica De Gregorio; Caterina Vivaldi; Elisa Paolicchi; Gianluca Masi; Fotios Loupakis; Elisa Sensi; Cristiana Lupi; Gabriella Fontanini; Yuzhuo Wang; Romano Danesi; Alfredo Falcone; Francesco Crea
Journal:  BMC Cancer       Date:  2015-11-09       Impact factor: 4.430

5.  EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.

Authors:  Qian Chen; Peng-Sheng Zheng; Wen-Ting Yang
Journal:  Oncotarget       Date:  2016-06-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.